论文部分内容阅读
目的探讨贲门部浸润性癌（Ｃ．Ｃａｓ）的预后；与幽门都浸润性癌（Ｐ．Ｃａｓ）进行对比分析。方法贲门部癌５０例，对照组幽门部癌５０例，采用临床病理学资料和免疫组织化学方法进行对比分析。结果 ①临床病理学，Ｃ．Ｃａｓ和Ｐ．Ｃａｓ之间除淋巴结转移（Ｐ＜０．０５）有显著差异外，其它无显著差异。②生存曲线分析，Ｃ．Ｃａｓ和Ｐ．Ｃａｓ之间，在淋巴结转移（Ｐ＜０．０１）和淋巴管侵入（Ｐ＜０．０５）方面有显著差异；在１００例进行性胃癌当中癌的浸润深度、淋巴结转移、淋巴管侵入以及ＴＮＭ分期等与预后有密切关系。③Ｃ．Ｃａｓ的ｃ－ｅｒｂＢ－２的表达率（Ｐ＜０．００１）和ＥＧＦＲ的表达率（Ｐ＜０．０５）与Ｐ．Ｃａｓ之间有显著差异。结论 淋巴结转移和淋巴管侵入是Ｃ．Ｃａｓ的最重要的预后因素；ｃ－ｅｒｂＢ－２和ＥＧＦＲ的阳性率或过表达，可间接反应Ｃ．Ｃａｓ的预后。
Objective To investigate the prognosis of invasive carcinoma of the cardia (C.Cas) and compare it with P.Cas. Methods A total of 50 patients with cardiac cancer were enrolled in this study. Fifty patients with pyloric carcinoma were included in the control group. The clinical pathology data and immunohistochemical methods were used for comparative analysis. Results 1 Clinical pathology, C. Cas and P. There was no significant difference between Cas except lymph node metastasis (P<0.05). 2 survival curve analysis, C. Cas and P. There was a significant difference in Cas between lymph node metastasis (P<0.01) and lymphatic invasion (P<0.05); infiltration depth, lymph node metastasis, lymphatic invasion, and TNM in 100 cases of progressive gastric cancer. Stages are closely related to prognosis. 3C. The expression rate of c-erbB-2 in Cas (P<0.001) and the expression rate of EGFR (P<0.05) and P. There are significant differences between Cas. Conclusion Lymph node metastasis and lymphatic invasion are C. The most important prognostic factor of Cas; the positive rate or overexpression of c-erbB-2 and EGFR can indirectly reflect C. The prognosis of Cas.